Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Speeding up the evaluation of new agents in cancer.

Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P.

J Natl Cancer Inst. 2008 Sep 3;100(17):1204-14. doi: 10.1093/jnci/djn267. Epub 2008 Aug 26.

2.

Specific keynote: clinical trial design problems in ovarian cancer.

Stevenson A, Gore M.

Gynecol Oncol. 2003 Jan;88(1 Pt 2):S117-21; discussion S122-3. Review. No abstract available.

PMID:
12586100
3.

Clinical trial designs for targeted agents.

Ma BB, Britten CD, Siu LL.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1287-305. Review.

PMID:
12512393
4.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials..

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

PMID:
18477802
5.

Integrated phase II/III clinical trials in oncology: a case study.

Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S.

Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22. Review.

PMID:
23180870
6.

A comparison of phase II study strategies.

Hunsberger S, Zhao Y, Simon R.

Clin Cancer Res. 2009 Oct 1;15(19):5950-5. doi: 10.1158/1078-0432.CCR-08-3205. Epub 2009 Sep 29. Review.

7.

Novel therapeutic strategies in development for prostate cancer.

Harzstark AL, Ryan CJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):13-22. Review.

PMID:
18095915
8.

Therapeutic studies.

Rubinstein LV.

Hematol Oncol Clin North Am. 2000 Aug;14(4):849-76, ix. Review.

PMID:
10949777
10.

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Kabbinavar FF, Ellis LM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. Review.

PMID:
15479482
11.

Expanding the clinical development of bevacizumab.

Chen HX.

Oncologist. 2004;9 Suppl 1:27-35. Review.

12.

Satraplatin: BMS 182751, BMY 45594, JM 216.

[No authors listed]

Drugs R D. 2007;8(2):125-32. Review.

PMID:
17324011
13.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
14.

Improving the design of phase II trials of cytostatic anticancer agents.

Stone A, Wheeler C, Barge A.

Contemp Clin Trials. 2007 Feb;28(2):138-45. Epub 2006 Jul 14. Review.

PMID:
16843736
15.

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Sharma MR, Maitland ML, Ratain MJ.

Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5. Review.

PMID:
19826363
16.
17.

Evolution of bevacizumab-based therapy in the management of breast cancer.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2008 Oct;8(5):402-10. doi: 10.3816/CBC.2008.n.048. Review.

PMID:
18952553
18.

Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.

Kelland L.

Expert Opin Investig Drugs. 2007 Jul;16(7):1009-21. Review.

PMID:
17594186
19.

Multi-arm clinical trials of new agents: some design considerations.

Freidlin B, Korn EL, Gray R, Martin A.

Clin Cancer Res. 2008 Jul 15;14(14):4368-71. doi: 10.1158/1078-0432.CCR-08-0325. Review.

20.

[Methodological approaches of clinical studies with targeted therapies].

Penel N, Saleron J, Lansiaux A, Clisant S, Adenis A, Fournier C, Duhamel A, Bonneterre J.

Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575. Review. French.

Supplemental Content

Support Center